← Back to Search

Behavioural Intervention

rTMS for Post-COVID Syndrome

N/A

Waitlist Available

Led By Helen Lavretsky, MD

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18+ years of age

Confirmed diagnosis of Long COVID

Must not have

Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system

Mentally or legally incapacitated or unable to give informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Summary

This trial is testing a treatment called rTMS for symptoms like fatigue and brain fog in people with Long-COVID. They will have 15 treatments with either active rTMS or fake stimulation

Who is the study for?

This trial is for individuals with Long-COVID experiencing fatigue, brain fog, and other neuropsychiatric symptoms. Participants will be selected from the UCLA Long-COVID clinic. Specific eligibility criteria are not provided but typically include a confirmed diagnosis of Long-COVID and meeting certain health standards.

What is being tested?

The study tests rTMS (repetitive Transcranial Magnetic Stimulation) against sham stimulation in patients with Long-COVID. It involves 15 treatments of either real or placebo rTMS followed by another 15 open-label treatments to assess changes in various symptoms like fatigue and cognitive impairment.

What are the potential side effects?

While specific side effects are not listed for this trial, common side effects of rTMS can include headache, scalp discomfort at the site of stimulation, tingling or spasms in facial muscles, lightheadedness, and rare risk of seizure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with Long COVID.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a neurological condition like epilepsy or severe head trauma.

Select...

I am unable to understand or sign the consent form due to mental or legal reasons.

Select...

My cognitive function test score is 24 or less.

Select...

I do not have infections or poor skin conditions on my scalp.

Select...

I am taking medication that can increase the risk of seizures.

Select...

I do not have severe depression with thoughts of suicide or psychosis.

Select...

I do not have uncontrolled asthma or serious health issues like heart disease, brain disorders, seizures, stroke, or diabetes.

Select...

I have never been diagnosed with bipolar, psychosis, intellectual disability, or had a suicide attempt in the last 2 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, after every 5th treatment, through study completion, an average of 12 weeks.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, after every 5th treatment, through study completion, an average of 12 weeks.

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, after every 5th treatment, through study completion, an average of 12 weeks. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Safety profile and adverse events

Tolerability as measured by Safteesi survey

Secondary study objectives

Alzheimer's Disease Assessment Scale (ADAS-Cog)

DKEFS CW

DKEFS CWI

+9 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: active rTMSActive Control1 Intervention

The rTMS magnet will be set to active stimulation without the knowledge of treating doctors or research team. Only one technician will know the randomization list assignment and will adjust the settings. rTMS treatment will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).

Group II: Sham rTMSPlacebo Group1 Intervention

The rTMS magnet will be set to sham stimulation without the knowledge of the treating doctors or the research team.

0 / 10Eligibility criteria met